94983-57-0Relevant academic research and scientific papers
Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same
-
Paragraph 0962-0965, (2018/05/17)
The present invention relates to a novel autotaxin inhibitor compound for preventing and treating disease or symptoms due to an increase in concentration of lysophosphatidic acid or activation of autotaxin. The present invention further relates to a pharmaceutical composition containing the same. The novel compound of the present invention is an autotaxin inhibitor which inhibits production of lysophosphatidic acid, and thus is useful for treating or preventing cardiovascular disease, cancer, metabolic disease, kidney disease, liver disease, inflammatory diseases, nervous disease, respiratory disease, desmoid disease, eye disease, cholestatic symptoms, other types of chronic pruritus or acute, or chronic rejection of transplanted organs.COPYRIGHT KIPO 2017
Photochemistry of Stable Pyridinyl Radicals. Photolysis of N-Alkyl-4-(carboalkoxy)pyridinyls
Takagi, Katsuhiko,Ogata, Yoshiro
, p. 989 - 992 (2007/10/02)
Photoinduced decomposition of N-benzyl-4-carbethoxypyridinyl (1a), N-methyl- (1b) and N-benzyl-4-(carbomethoxy)pyridinyl (1c), and their mixture was studied in degassed acetonitrile.N-benzyl homologues (1a and 1c) were smoothly photolyzed to ethyl (or methyl) isonicotinate by loss of a benzyl group, whereas the N-methyl homologue (1b) was comparatively stable toward UV light; the rate of disappearance of 1c relative to that of 1b was 11:1.A mechanism is postulated, which involves the formation of an alkyl radical by C-N bond homolysis followed by attack on the pyridinyl radical to form dihydropyridines.This is supported by a plot of the yield of ethyl isonicotinate vs. the ratio of initial concentrations 0/0.Pyridinyl radicals 1 possess their absorption maxima at around 300, 395, and 630 nm; those at 300 and 395 nm maxima participate in this reaction.
